Paul M. Beringer

1.9k total citations
64 papers, 1.4k citations indexed

About

Paul M. Beringer is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Paul M. Beringer has authored 64 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 18 papers in Pharmacology and 17 papers in Epidemiology. Recurrent topics in Paul M. Beringer's work include Cystic Fibrosis Research Advances (30 papers), Antibiotics Pharmacokinetics and Efficacy (18 papers) and Antibiotic Resistance in Bacteria (10 papers). Paul M. Beringer is often cited by papers focused on Cystic Fibrosis Research Advances (30 papers), Antibiotics Pharmacokinetics and Efficacy (18 papers) and Antibiotic Resistance in Bacteria (10 papers). Paul M. Beringer collaborates with scholars based in United States, South Korea and Norway. Paul M. Beringer's co-authors include Annie Wong‐Beringer, Roger W. Jelliffe, Edmund Tse, Stan G. Louie, Mark A. Gill, Adupa P. Rao, Bertrand J. Shapiro, Richard L. Slaughter, Alexander A. Vinks and Maria D. Appleman and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Paul M. Beringer

59 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul M. Beringer United States 22 500 362 348 333 286 64 1.4k
Olivier Petitjean France 22 667 1.3× 450 1.2× 213 0.6× 246 0.7× 330 1.2× 89 1.6k
Lavern M. Vercaigne Canada 20 700 1.4× 625 1.7× 222 0.6× 297 0.9× 481 1.7× 40 1.7k
Olaf Burkhardt Germany 27 728 1.5× 1.0k 2.8× 218 0.6× 422 1.3× 390 1.4× 56 2.1k
William Salzer United States 14 323 0.6× 300 0.8× 207 0.6× 257 0.8× 121 0.4× 26 2.1k
Nicolas Grégoire France 24 808 1.6× 551 1.5× 317 0.9× 137 0.4× 875 3.1× 73 1.7k
Jerina Boelens Belgium 20 262 0.5× 734 2.0× 293 0.8× 487 1.5× 181 0.6× 83 1.8k
Michael G. Spigarelli United States 25 492 1.0× 487 1.3× 367 1.1× 257 0.8× 153 0.5× 78 1.5k
P Periti Italy 21 450 0.9× 505 1.4× 231 0.7× 216 0.6× 175 0.6× 107 1.9k
Guy W. Amsden United States 22 383 0.8× 577 1.6× 288 0.8× 284 0.9× 134 0.5× 68 1.4k
Heino Staß Germany 21 614 1.2× 424 1.2× 256 0.7× 171 0.5× 280 1.0× 54 1.2k

Countries citing papers authored by Paul M. Beringer

Since Specialization
Citations

This map shows the geographic impact of Paul M. Beringer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Beringer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Beringer more than expected).

Fields of papers citing papers by Paul M. Beringer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Beringer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Beringer. The network helps show where Paul M. Beringer may publish in the future.

Co-authorship network of co-authors of Paul M. Beringer

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Beringer. A scholar is included among the top collaborators of Paul M. Beringer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Beringer. Paul M. Beringer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beringer, Paul M., et al.. (2025). Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity. Clinical Pharmacology & Therapeutics. 119(1). 208–218.
2.
3.
Zampoli, Marco, et al.. (2024). Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clinical Pharmacology & Therapeutics. 115(6). 1204–1207. 4 indexed citations
4.
5.
Beringer, Paul M., et al.. (2024). Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury. mSphere. 9(11). e0067124–e0067124. 2 indexed citations
6.
7.
Beringer, Paul M., et al.. (2023). Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications. Expert Opinion on Drug Metabolism & Toxicology. 19(4). 203–216. 7 indexed citations
8.
Tran, Dat Q., Justin B. Schaal, Patti Tran, et al.. (2019). Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms. Scientific Reports. 9(1). 16905–16905. 16 indexed citations
9.
Schaal, Justin B., et al.. (2017). Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. American Journal of Respiratory Cell and Molecular Biology. 58(3). 310–319. 21 indexed citations
10.
Wirth, W., S. Maschek, Paul M. Beringer, & F. Eckstein. (2017). Subregional laminar cartilage MR spin–spin relaxation times (T2) in osteoarthritic knees with and without medial femorotibial cartilage loss – data from the Osteoarthritis Initiative (OAI). Osteoarthritis and Cartilage. 25(8). 1313–1323. 17 indexed citations
11.
Schaal, Justin B., Dat Q. Tran, Reshma Patel, et al.. (2017). Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide. PLoS ONE. 12(11). e0187868–e0187868. 12 indexed citations
12.
Beringer, Paul M., Henry C. Ho, Melissa Agnello, et al.. (2015). Rhesus θ-defensin-1 (RTD-1) exhibitsin vitroandin vivoactivity against cystic fibrosis strains ofPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 71(1). 181–188. 22 indexed citations
13.
Rao, Adupa P., et al.. (2012). Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulmonary Pharmacology & Therapeutics. 25(5). 377–382. 9 indexed citations
14.
Beringer, Paul M., et al.. (2008). GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. Journal of Cystic Fibrosis. 8(1). 19–25. 32 indexed citations
15.
Swadron, Stuart P., et al.. (2004). A Comparison of Phenytoin-loading Techniques in the Emergency Department. Academic Emergency Medicine. 11(3). 244–252. 29 indexed citations
16.
Louie, Stan G., et al.. (2002). Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine. 8(6). 521–528. 22 indexed citations
17.
Beringer, Paul M., et al.. (2002). Development of Population Pharmacokinetic Models and Optimal Sampling Times for Ibuprofen Tablet and Suspension Formulations in Children With Cystic Fibrosis. Therapeutic Drug Monitoring. 24(2). 315–321. 10 indexed citations
18.
Beringer, Paul M.. (2001). The clinical use of colistin in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine. 7(6). 434–440. 100 indexed citations
19.
Montgomery, Megan J., Paul M. Beringer, Stan G. Louie, & Mark A. Gill. (2000). Estimation of Creatinine Clearance in Patients With Metastatic Ovarian Cancer. Therapeutic Drug Monitoring. 22(6). 695–700. 10 indexed citations
20.
Beringer, Paul M.. (1999). New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine. 5(6). 371–371. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Petitjean Breakdown of academic impact, for papers by Lavern M. Vercaigne Breakdown of academic impact, for papers by Olaf Burkhardt Breakdown of academic impact, for papers by William Salzer Breakdown of academic impact, for papers by Nicolas Grégoire Breakdown of academic impact, for papers by Jerina Boelens Breakdown of academic impact, for papers by Michael G. Spigarelli Breakdown of academic impact, for papers by P Periti Breakdown of academic impact, for papers by Guy W. Amsden Breakdown of academic impact, for papers by Heino Staß
Rankless by CCL
2026